Table 5.

Association of aspirin treatment with risk of adenoma recurrence stratified by ODC genotypes, Aspirin/Folate Polyp Prevention Study, 1994–2001

[No. of controls/cases] RR (95% CI)
SNPPlacebo81 mg/d aspirin325 mg/d aspirinPint
rs2430420
 GG[58/58] 1.0 (referent)[76/40] 0.68 (0.50–0.94)[75/50] 0.81 (0.61–1.09)
 GA/AA[70/67] 1.0 (referent)[85/70] 0.95 (0.75–1.20)[58/85] 1.22 (0.98–1.53)0.06
rs28362380
 TT[98/106] 1.0 (referent)[136/84] 0.75 (0.61–0.92)[105/110] 0.97 (0.80–1.18)
 TC/CC[30/19] 1.0 (referent)[24/26] 1.32 (0.85–2.06)[28/25] 1.24 (0.80–1.94)0.06
rs2302615a
 GG[72/59] 1.0 (referent)[78/65] 0.97 (0.75–1.25)[71/76] 1.11 (0.87–1.42)
 AG/AA[49/64] 1.0 (referent)[75/44] 0.65 (0.47–0.88)[54/58] 0.96 (0.73–1.26)0.25

Abbreviation: Pint = P for interaction (between aspirin treatment and genotype, modeled dominantly).

  • aPreviously genotyped SNP (17).